Genmab — Maj 2014
-
Key Findings:
• GA101 activates ADCC in cultured human B-cell cancer cells using human
PBMCs or an engineered cell line that expresses FcγRIIIa (Report 1025241,
reviewed below). The ADCC activity is greater in side-by-side comparisons with
rituximab but the magnitude of differences varies with the concentrations of
mAbs used. The addition of nonspecific human IgGs reduces the ADCC
activated by either GA101 or rituximab. -
• The ability of GA101, rituximab and ofatumumab to activate ADCP was
compared using M1 and M2c macrophages generated from human monocytederived
macrophages.14 No significant differences were observed between the
three antibodies with respect to ADCP, in the presence or absence of competing
endogenous human IgGs.
• GA101 binds to either FcγRIIIa 158V/F variant with greater affinity than rituximab -
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125486Orig1s000PharmR.pdf Gazyva bruger også ADCC - så vidt jeg forstod på det ....
-
ja men Gazyva i høje koncentrationer = fucking giftigt
-
og Arzerra er jo stadig langt bedre på CDC end Rituxan?
-
hvis ikke vi hører noget idag skal vi nok konkludere at de har villet have flere oplysninger og derfor ingen beslutning har taget
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind